[go: up one dir, main page]

TR201910701T4 - Kanser terapisine yönelik ro5503781 ve kapesitabin kombinasyonu. - Google Patents

Kanser terapisine yönelik ro5503781 ve kapesitabin kombinasyonu. Download PDF

Info

Publication number
TR201910701T4
TR201910701T4 TR2019/10701T TR201910701T TR201910701T4 TR 201910701 T4 TR201910701 T4 TR 201910701T4 TR 2019/10701 T TR2019/10701 T TR 2019/10701T TR 201910701 T TR201910701 T TR 201910701T TR 201910701 T4 TR201910701 T4 TR 201910701T4
Authority
TR
Turkey
Prior art keywords
capecitabine
combination
cancer therapy
question
product
Prior art date
Application number
TR2019/10701T
Other languages
English (en)
Inventor
Higgins Brian
Nichols Gwen
E Packman Kathryn
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TR201910701T4 publication Critical patent/TR201910701T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Burada, kanserin eş zamanlı veya art arda gerçekleştirilen tedavisine yönelik a) aşağıda yer alan formül bileşiğini içeren bir birinci bileşeni ve b) kapesitabin içeren bir ikinci bileşeni içeren farmasötik ürünler, söz konusu ürünü içeren kitler ve aynı zamanda söz konusu ürünün uygulanmasıyla kanser hastalarının tedavi edilmesine yönelik yöntemler sağlanmıştır.
TR2019/10701T 2013-06-19 2014-06-16 Kanser terapisine yönelik ro5503781 ve kapesitabin kombinasyonu. TR201910701T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361836894P 2013-06-19 2013-06-19

Publications (1)

Publication Number Publication Date
TR201910701T4 true TR201910701T4 (tr) 2019-08-21

Family

ID=50981495

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10701T TR201910701T4 (tr) 2013-06-19 2014-06-16 Kanser terapisine yönelik ro5503781 ve kapesitabin kombinasyonu.

Country Status (14)

Country Link
US (1) US20160129033A1 (tr)
EP (1) EP3010513B1 (tr)
JP (1) JP6239745B2 (tr)
KR (1) KR20160007662A (tr)
CN (1) CN105307660A (tr)
BR (1) BR112015029658A2 (tr)
CA (1) CA2912816A1 (tr)
ES (1) ES2741003T3 (tr)
HK (1) HK1214502A1 (tr)
MX (1) MX2015016893A (tr)
PL (1) PL3010513T3 (tr)
RU (1) RU2015152577A (tr)
TR (1) TR201910701T4 (tr)
WO (1) WO2014202492A1 (tr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050227932A1 (en) * 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
US8232298B2 (en) * 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53
CN101405281B (zh) * 2006-03-22 2013-12-11 詹森药业有限公司 Mdm2和p53相互作用的抑制剂
US8367699B2 (en) * 2006-09-15 2013-02-05 Nexuspharma, Inc. Tetrahydro-isoquinolines
JP5053674B2 (ja) * 2007-03-26 2012-10-17 テルモ株式会社 耳式体温計
KR101434009B1 (ko) * 2008-08-04 2014-08-25 와이어쓰 엘엘씨 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
CA2912816A1 (en) 2014-12-24
HK1214502A1 (zh) 2016-07-29
JP2016522228A (ja) 2016-07-28
CN105307660A (zh) 2016-02-03
RU2015152577A (ru) 2017-07-24
ES2741003T3 (es) 2020-02-07
EP3010513A1 (en) 2016-04-27
US20160129033A1 (en) 2016-05-12
PL3010513T3 (pl) 2019-11-29
WO2014202492A1 (en) 2014-12-24
KR20160007662A (ko) 2016-01-20
BR112015029658A2 (pt) 2017-07-25
MX2015016893A (es) 2016-04-07
EP3010513B1 (en) 2019-06-05
JP6239745B2 (ja) 2017-11-29

Similar Documents

Publication Publication Date Title
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1120506T1 (el) Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων
TW201613887A (en) Antiproliferative compounds and methods of use thereof
BR112016000561B8 (pt) Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
MX383590B (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
MX340090B (es) Analogos de spliceostatina.
EA201391106A1 (ru) Новые гетероциклические производные
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
EA201591024A1 (ru) Димерные соединения
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
MX2018006953A (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer.
EA201591450A1 (ru) Фармацевтический состав, содержащий гликозаминогликан